Diaceutics (LON:DXRX) Posts Quarterly Earnings Results

Diaceutics (LON:DXRX) posted its quarterly earnings results on Tuesday. The company reported GBX (3.27) EPS for the quarter, Digital Look Earnings reports. Diaceutics had a negative return on equity of 0.68% and a negative net margin of 0.66%.

Diaceutics Stock Performance

Shares of DXRX stock traded down GBX 7.14 during mid-day trading on Friday, hitting GBX 185.86. The stock had a trading volume of 727,923 shares, compared to its average volume of 209,587. The firm has a market cap of £157.72 million, a PE ratio of 1,689.61 and a beta of 0.88. The company’s 50-day simple moving average is GBX 149.18 and its 200-day simple moving average is GBX 151.79. The company has a debt-to-equity ratio of 5.40, a current ratio of 2.55 and a quick ratio of 9.92. Diaceutics has a fifty-two week low of GBX 125 and a fifty-two week high of GBX 197.

Analyst Ratings Changes

Separately, Canaccord Genuity Group reiterated a “buy” rating and issued a GBX 215 price objective on shares of Diaceutics in a report on Tuesday. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of GBX 215.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.